Company profile: Bilthoven Biologicals
1.1 - Company Overview
Company description
- Provider of pharmaceutical products manufacturing services and vaccine/diagnostic solutions, including inactivated polio vaccine (IPV), pandemic preparedness vaccine facilities in Europe (capacity over 300 million doses annually), SIILTIBCY tuberculosis skin test, BCG for bladder cancer and TB vaccination, DTP vaccine (diphtheria, tetanus, polio), and tetanus vaccine.
Products and services
- Pandemic Preparedness Vaccine Facilities: High-capacity infrastructure engineered to ensure vaccine accessibility in Europe during pandemics, with production capability exceeding 300 million doses annually
- Poliomyelitis Vaccine (IPV): Inactivated vaccine employed in the global polio eradication program, stimulating protective antibody production without causing disease for safe immunization
- DTP Vaccine: Trivalent combination product for diphtheria, tetanus, and polio, available as a primary or booster vaccination
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Bilthoven Biologicals
Celldex Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage antibody-based therapeutics, including monoclonal and bispecific antibodies, targeting inflammatory, allergic, autoimmune, and other severe diseases. Pipeline includes barzolvolimab (KIT inhibitor for mast cell-driven diseases) and CDX-585 (PD-1/ILT4 bispecific for solid tumors). Services include conducting clinical trials and offering compassionate use/expanded access programs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Celldex Therapeutics company profile →
Abcuro
HQ: United States
Website
- Description: Provider of immunotherapies for autoimmunity and cancer, including ABC008, a monoclonal antibody targeting KLRG1 to selectively deplete highly cytotoxic T cells in inclusion body myositis, T-cell large granular lymphocytic leukemia, and certain cancers, and ABC015, a preclinical antibody blocking KLRG1-ligand interaction to activate cytotoxic T and NK cells; conducts clinical trials for ABC008 in IBM and T-LGLL.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Abcuro company profile →
Etna Biotech
HQ: Italy
Website
- Description: Provider of vaccine and immunotherapeutic research and development for infectious diseases, with candidates targeting Hepatitis E, Congo Hemorrhagic fever, Leishmaniasis (Kala Azar), malaria, HPV (to prevent cervical cancer and genital warts), and seasonal and pandemic influenza.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Etna Biotech company profile →
Confluence Life Sciences
HQ: United States
Website
- Description: Provider of rational drug design-based discovery and development of mechanistically novel kinase inhibitors for human and animal health care, targeting key signal transduction enzymes involved in regulating cancer growth and survival and modulating chronic inflammation.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Confluence Life Sciences company profile →
MetrioPharm
HQ: Switzerland
Website
- Description: Provider of clinical-stage pharmaceutical development for chronic inflammatory diseases including psoriasis, arthritis, and multiple sclerosis. Offers MP1032, an oral immune modulator that normalizes energy metabolism of inflammatory immune cells and reduces corticosteroid-associated side effects without immunosuppression, with Phase IIa efficacy in psoriasis and COVID-19 and preclinical efficacy in Rheumatoid Arthritis and Duchenne muscular dystrophy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MetrioPharm company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Bilthoven Biologicals
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Bilthoven Biologicals
2.2 - Growth funds investing in similar companies to Bilthoven Biologicals
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Bilthoven Biologicals
4.2 - Public trading comparable groups for Bilthoven Biologicals
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →